Novel antibody–drug conjugates: current and future roles in gynecologic oncology
| العنوان: | Novel antibody–drug conjugates: current and future roles in gynecologic oncology |
|---|---|
| المؤلفون: | Alessandro D. Santin, Burak Zeybek, Joan Tymon-Rosario |
| المصدر: | Curr Opin Obstet Gynecol |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Drug, Immunoconjugates, Genital Neoplasms, Female, media_common.quotation_subject, Gynecologic oncology, Ado-Trastuzumab Emtansine, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Antigen, Cell Line, Tumor, Bystander effect, Humans, Medicine, media_common, 030219 obstetrics & reproductive medicine, biology, business.industry, Obstetrics and Gynecology, Cancer, Trastuzumab, medicine.disease, body regions, chemistry, Trastuzumab emtansine, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Sacituzumab govitecan, Female, Antibody, business |
| الوصف: | Purpose of review Antibody-drug conjugates (ADCs) represent a new class of drugs that combine a surface receptor-targeting antibody linked to a cytotoxic molecule. This review summarizes the current literature demonstrating their tremendous promise as therapeutic agents in the treatment of aggressive gynecologic malignancies. Recent findings Several antigens have proven to be differentially overexpressed in a variety of gynecologic tumors when compared with normal surrounding tissue and serve as novel targets for ADC therapy. In the last few years HER2/neu, folic acid-alpha (FRα) and Trop-2 overexpression have been exploited as excellent targets by novel ADCs such as Trastuzumab emtansine (T-DM1), SYD985, IMGN853 (Mirvetuximab soravtansine) and Sacituzumab govitecan (SG, IMMU-132) in multiple tumors including ovarian, endometrial and cervical cancers. Although the selectivity of ADCs with noncleavable linkers (i.e. T-DM1) has shown negligible effect on surrounding antigen negative cells, those ADCs with cleavable linkers (i.e. SYD985, IMGN853 and SG) may kill both antigen-positive target cells and surrounding antigen-negative cells via the bystander effect. Summary Preclinical data strongly supports these ADCs and ongoing clinical trials will shed further light into the potential of making these drugs part of current standard practice and providing our patients with a higher level of personalized cancer care. |
| تدمد: | 1473-656X 1040-872X |
| DOI: | 10.1097/gco.0000000000000642 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa0095c3fe4fe85209d796af9e7fd668 https://doi.org/10.1097/gco.0000000000000642 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fa0095c3fe4fe85209d796af9e7fd668 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1473656X 1040872X |
|---|---|
| DOI: | 10.1097/gco.0000000000000642 |